Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Editor’s Pick: Five Healthcare News Headlines for September 14 - September 27
September 29, 2015
- MHLW Gives Greenlight to AbbVie’s Hep C Drug, Other Products
September 29, 2015
- Health Policy Bureau Chief Futagawa Tapped for MHLW’s Top Bureaucratic Post
September 28, 2015
- PMDA Reviewing Daklinza, Sunvepra for Risk of Interstitial Pneumonia
September 28, 2015
- MHLW OKs New Indications for Xarelto, Lamictal, Other Products
September 25, 2015
- Drug Pricing Tomorrow: Full Interview with MOF Budget Examiner Unami
September 25, 2015
- One-Month Lag in Regulatory Filing Accepted for Sakigake Designation
September 24, 2015
- Pharmaceutical Affairs Council Approves Basic Plan for “Humanitarian Trials”
September 24, 2015
- Panel OKs Revised Japanese Pharmacopoeia, 76 Products Newly Included
September 18, 2015
- MHLW to Continue to Suspend HPV Vaccine Recommendation
September 18, 2015
- 51 Products Officially Filed for Sakigake Designation after MHLW Screening
September 18, 2015
- Add Myasthenia Gravis, Myositis to Opdivo Label: MHLW
September 17, 2015
- Toxic Epidermal Necrolysis Added to Clinically Significant ADR List for Vectibix
September 17, 2015
- Editor’s Pick: Five Healthcare News Headlines for August 24 - September 13
September 15, 2015
- Japan to Help Fight Infectious Diseases in Developing Nations: Basic Policy
September 15, 2015
- Bevacizumab, 2 Other Compounds Designated as Orphan Drugs
September 15, 2015
- Kaketsuken Reports Results of Internal Probe on Improper Blood Product Manufacturing
September 11, 2015
- 1 Million Signatures Collected Opposing Exclusion of Kampo from Reimbursement; “Discussion Closed”: LDP Kampo Supporters
September 11, 2015
- MHLW Reports on “Comprehensive Strategy” at Chuikyo
September 10, 2015
- Drug Pricing Tomorrow: Full Interview with MHLW Councilor Takeda - Part 2
September 10, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…